Skip to main content
598 search results for:

Non-small cell lung cancer 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 18-10-2022 | Non-small-cell lung cancer | Adis Journal Club | Article
    BioDrugs

    Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options

    Trastuzumab deruxtecan was also recently Food and Drug Administration (FDA) approved for non-small cell lung cancer with  HER2  mutations.

  2. 01-08-2022 | Non-small-cell lung cancer | Adis Journal Club | Article
    Targeted Oncology

    Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis

    Objective The aim of this study was to compare the efficacy and toxicity of checkpoint inhibitors between RCTs and RWE studies in patients with advanced non-small cell lung cancer (NSCLC) or melanoma.

  3. 16-03-2022 | Osimertinib | Adis Journal Club | Article
    Oncology and Therapy

    ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

    Authors: Ana Ortega-Franco & Shereen Rafee Abstract The introduction of tyrosine kinase inhibitors (TKI) for the treatment of metastatic non-small cell lung cancer (NSCLC) harbouring sensitizing epidermal growth factor receptor (EGFR) gene mutations revolutionized the diagnostic and treatment algorithm of this subset of patients almost two decades ago.

  4. 18-10-2021 | Immunotherapy | Adis Journal Club | Article
    Oncology and Therapy

    Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota

    DOI [Teaser] Key Summary Points Non-small cell lung cancer (NSCLC) patients with and without response to PD-I immunotherapy have different diversity and composition of gut microbiota.

  5. 13-01-2022 | ALK-mutated NSCLC | Adis Journal Club | Article
    Targeted Oncology

    Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System

    Authors: Monia Sisi, Michele Fusaroli, Andrea De Giglio, Francesco Facchinetti, Andrea Ardizzoni, Emanuel Raschi & Francesco Gelsomino Abstract Background The development of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) has improved the survival outcomes of patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC).

  6. 10-08-2021 | Adis Journal Club | Article
    Oncology and Therapy

    What is the Definition of Cure in Non-small Cell Lung Cancer?

    Despite the high mortality of non-small cell lung cancer, surgery and radiotherapy with curative intent can be offered if the disease is caught at an early stage.

  7. 01-10-2021 | Non-small-cell lung cancer | Adis Journal Club | Article
    PharmacoEconomics

    Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review

    DOI [Teaser] Key Points for Decision Makers The dominant approaches to modeling the cost effectiveness of immuno-oncology (IO) therapies in advanced non-small cell lung cancer are Markov and partitioned survival models.

  8. 23-01-2022 | EGFR-mutated NSCLC | Adis Journal Club | Article
    Oncology and Therapy

    Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature

    DOI [Teaser] Key Summary Points Treatment with immune checkpoint inhibitors is generally poorly effective for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients who experience acquired resistance to an EGFR-tyrosine kinase inhibitor (TKI).

  9. 17-09-2021 | Non-small-cell lung cancer | Adis Journal Club | Article
    Drugs - Real World Outcomes

    European and US Real-World Treatment Patterns in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Retrospective Medical Record Review

    Davis, Parisa Karimi, William Sawyer, Ning Yu, Aliki Taylor & Josephine Feliciano Abstract Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line (1L) therapy for EGFR mutation-positive (EGFRm) advanced/metastatic non-small cell lung cancer (NSCLC).

  10. 04-01-2018 | Non-small-cell lung cancer | Editorial | Article

    Chemotherapy-immunotherapy combinations in non-small cell lung cancer: embracing an opportunity

    The stark reality is that lung cancer is an unforgiving disease.

  11. 16-04-2018 | Pembrolizumab | Article

    Pembrolizumab plus Chemotherapy in Metastatic NonSmall-Cell Lung Cancer

    Gandhi L et al. N Eng J Med 2018. 10.1056/NEJMoa1801005

  12. 24-01-2018 | Non-small-cell lung cancer | Article

    The biology and management of non-small cell lung cancer

    Herbst RS et a.  Nature  2018; 553: 446–454. doi:10.1038/nature25183

  13. 23-01-2018 | Non-small-cell lung cancer | Article

    Pembrolizumab-chemotherapy combination in non-small cell lung cancer: Introduction

    Two editorials provide differing opinions on using pembrolizumab with pemetrexed and platinum chemotherapy for non-small cell lung cancer. In the first article, Stephen Liu argues for embracing this new treatment option, while in the second, Sally Lau and Natasha Leighl argue for a little more caution.

  14. 16-08-2018 | Non-small-cell lung cancer | Article

    Management of EGFR mutation-positive non-small-cell lung cancer: Two steps forward, looking back

    Caroline McCoach (Helen Diller Family Comprehensive Cancer Center, CA, USA) and Howard (Jack) West (Swedish Cancer Institute, WA, USA) discuss the way forward after great progress with tyrosine kinase inhibitors targeting the epidermal growth factor receptor in non-small-cell lung cancer.

  15. 05-02-2018 | Immunotherapy | View from the clinic | Article

    Explaining immunotherapy to our patients with non-small cell lung cancer

    Immunotherapy is changing practice in lung cancer, and with this, patient education. In this 'View from the clinic' article, Advisory Board member Beth Eaby-Sandy describes how she explains the new immunotherapy treatments to her patients. 

  16. 18-11-2017 | Non-small-cell lung cancer | Article

    Osimertinib in Untreated EGFR-Mutated Advanced NonSmall-Cell Lung Cancer

    Soria JC et al.  N Engl J Med  2018; 378(2): 113-125. doi:10.1056/NEJMoa1713137

  17. 27-07-2017 | Non-small-cell lung cancer | Book chapter | Article

    Liquid biopsy in non-small cell lung cancer (NSCLC)

    Rolfo C et al. In: Liquid Biopsy in Cancer Patients . Edited by Russo A, Giordano A, Rolfo C. Humana Press, Cham, 2017. doi: 10.1007/978-3-319-55661-1_12

  18. 26-07-2017 | Non-small-cell lung cancer | Editorial | Article

    Changing landscape of treatment for ALK-positive non-small cell lung cancer

    Tremendous advances have been made in the treatment of ALK-positive lung cancers. Advisory Board member Fiona Blackhall summarizes recent developments in the field and discusses current management hurdles, including development of resistance to ALK inhibitors.

  19. 05-03-2018 | Non-small-cell lung cancer | Article

    SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

    Dardaei L et al. Nat Med 2018. doi:10.1038/nm.4497

  20. 20-07-2017 | Lung and thoracic tumors | Article

    Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer

    ​​​​​​​ Br J Cancer  2017; 117: 744–751. doi:10.1038/bjc.2017.232

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.